Multiple Sclerosis and Neuroimmunology Clinical Trials

Analysis of Cytokine Modulation with Tecfidera in Human Immune Cell Subsets Using High Dimensional Flow Cytometry and CYTOF Mass Spectrometry
Eprotocol number 29046
This is an open label longitudinal study analyzing peripheral blood lymphocyte subsets in patients with Relapsing Remitting Multiple Scleorsis (RRMS) that are on Tecfidera.
PI: Lawrence Steinman
Actively enrolling

Blood, CSF and Tissue Repository To Identify Biomarkers in Multiple Sclerosis
Stanford Protocol #16691
Sponsor: Stanford University
PI: May Han, MD
Study Active, Enrollment Open

A Randomized Controlled Trial of Vitamin D in Multiple Sclerosis
NCT01490502
Sponsor: Johns Hopkins University, National MS Society
PI: Jeffrey Dunn, MD
closed to enrollment, closed to study activities

Multicenter, Randomized, Double-Blind, Parallel-Group Extension to Study AC-058B201 to Investigate the Long-Term Safety, Tolerability, and Efficacy of 10, 20, and 40 mg/day ACT-128800, an Oral S1P1 Receptor Agonist, in Patients with Relapsing-Remitting Multiple Sclerosis
NCT01093326
AC-058B202
Sponsor: Actelion Pharmaceuticals Ltd
PI: Jeffrey Dunn, MD
Study Active, Enrollment Closed

A Randomized, Double-blind, Double-dummy, Parallel-group Study to Evaluate the Efficacy and Safety of Ocrelizumab in Comparison to Interferon Beta-1a (Rebif ®) in Patients with Relapsing Multiple Sclerosis
NCT01412333
WA21093
Sponsor: Genentech
PI: Jeffrey Dunn, MD
Study is closed to enrollment, Open Label Extension is ongoing

A Double-Blind, Placebo-Controlled, Single Ascending Intravenous Infusion Study of rHIgM22 in Patients with Multiple Sclerosis              
NCT01803867
IM22-MS-1004
Sponsor: Acorda
PI: Jeffrey Dunn, MD
Study Active, Enrollment Closed

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex
NCT01864148
215MS201
Sponsor: Biogen Idec
PI: Viet Nguyen, MD
Study Active, Enrollment Closed